Prior to joining Tmunity, Dr. Coughlin was Chief Medical Officer at British biotechnology company, Immunocore Ltd., where she was responsible for leading the effort to develop novel bispecific T cell receptor-based biologics for cancer immunotherapy. Dr. Coughlin led the clinical efforts and developed the pivotal program around the gp100-specific TCR bispecific in uveal melanoma. Prior to that, she led early development programs at Novartis, including development teams investigating checkpoint inhibition and PI3?kinase inhibition. She has both biotechnology and large pharmaceuticals experience, having held senior medical positions at Morphotek (Eisai), Pfizer and Wyeth. Dr. Coughlin began her career as a physician-scientist at the University of Pennsylvania and the Children's Hospital of Philadelphia. There, Dr. Coughlin studied patient responses to tumor antigens with Dr. Robert Vonderheide in the division of Translational Research under the direction of Dr. Carl June. She holds a BS from Temple University and an MD and PhD from the University of Pennsylvania. She completed her residency and a hematology/oncology fellowship at Children?s Hospital of Philadelphia, as well as a research post-doctoral fellowship at the University of Pennsylvania.